Sclareol (SC) is arousing great interest due to its cytostatic and cytotoxic activities in several cancer cell lines. However, its hydrophobicity is a limiting factor for its in vivo administration. One way to solve this problem is through nanoencapsulation. Therefore, solid lipid nanoparticles (SLN-SC) and nanostructured lipid carriers (NLC-SC) loaded with SC were produced and compared regarding their physicochemical properties. NLC-SC showed better SC encapsulation than SLN-SC and was chosen to be compared with free SC in human cancer cell lines (MDA-MB-231 and HCT-116). Free SC had slightly higher cytotoxicity than NLC-SC and produced subdiploid DNA content in both cell lines. On the other hand, NLC-SC led to subdiploid content in MDA-MB...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause ...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Ci...
This article describes the development of nanostructured lipid carriers (NLC) as colloidal carriers ...
Drug delivery systems have opened new avenues to improve the therapeutic effects of already-efficien...
More than half of all people diagnosed with cancer receive chemotherapy. Unfortunately, most chemoth...
A brief introduction to solid lipid nanoparticles (SLN) is provided and the reasoning behind the use...
Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemi...
Solid lipid nanoparticles (SLN) present low toxicity, versatility to incorporate both lipophilic and...
The efficacy of current standard chemotherapy is suboptimal due to the poor solubility and short hal...
Cancer is a leading cause of death in many countries around the world. However, the efficacy of curr...
During the past decade, the number of studies describing nanostructured lipid carriers (NLC)-based f...
Artemether (ART) was combined with triglyceride of docosahexaenoic acid (DHA) as the lipid-core in n...
Cancer stem cells (CSCs) are resistant to conventional chemotherapy and have a strong potential to g...
Recently more focus has been put to the development of innovative drug-delivery systems that include...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause ...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Ci...
This article describes the development of nanostructured lipid carriers (NLC) as colloidal carriers ...
Drug delivery systems have opened new avenues to improve the therapeutic effects of already-efficien...
More than half of all people diagnosed with cancer receive chemotherapy. Unfortunately, most chemoth...
A brief introduction to solid lipid nanoparticles (SLN) is provided and the reasoning behind the use...
Ideally, antineoplastic treatment aims to selectively eradicate cancer cells without causing systemi...
Solid lipid nanoparticles (SLN) present low toxicity, versatility to incorporate both lipophilic and...
The efficacy of current standard chemotherapy is suboptimal due to the poor solubility and short hal...
Cancer is a leading cause of death in many countries around the world. However, the efficacy of curr...
During the past decade, the number of studies describing nanostructured lipid carriers (NLC)-based f...
Artemether (ART) was combined with triglyceride of docosahexaenoic acid (DHA) as the lipid-core in n...
Cancer stem cells (CSCs) are resistant to conventional chemotherapy and have a strong potential to g...
Recently more focus has been put to the development of innovative drug-delivery systems that include...
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib w...
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause ...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Ci...